A Phase 1 trial (Regenerate MSA-101) is underway to evaluate the effects of AB-1005 (AAV2-GDNF) in patients affected by MSA-parkinsonian type (MSA-P) (NCT05167721. The gene discussed is GDNF; the disease is multiple system atrophy.